Delcath Systems markets Hepzato Kit for the treatment of uveal melanoma with unresectable hepatic metastases. Click here to read my analysis of DCTH stock.

Mayo Clinic researchers have developed organoid models to study uveal melanoma, one of the most common types of eye cancer in ...

Mayo Clinic researchers have developed organoid models to study uveal melanoma, one of the most common types of eye cancer in ...

Do you have blue eyes? We talked to experts to discover curious facts about baby blues, including whether your biological ...

Mayo Clinic researchers have developed organoid models to study uveal melanoma, one of the most common types of eye cancer in adults. Their goal is to use these models to better understand how this ...

Uveal melanoma is the most common primary malignancy of the eye and frequently leads to metastatic death. Until the mid-20th Century, the only treatment for uveal melanoma was enucleation.

ROCHESTER, Minnesota — Mayo Clinic researchers have developed  organoid models  to study  uveal melanoma , one of the most common types of eye cancer ...

Turnstone, which went public via an $80 million IPO in 2023, ended September 2024 with $45.3 million to hand, which the ...

The company is also carrying out a pair of phase 3 trials in cutaneous melanoma – PRISM-MEL-301 and TEBE-AM – and is due to start a third in adjuvant uveal melanoma (ATOM) before year-end.

Detailed price information for Delcath Systems Inc (DCTH-Q) from The Globe and Mail including charting and trades.